What MSD Belgium does

MSD Belgium is the Belgian commercial subsidiary of Merck & Co., Inc. (NYSE: MRK), a global biopharmaceutical company headquartered in Rahway, New Jersey. Established in Belgium in 1965 and operating from Brussels with 234 employees, the subsidiary markets innovative prescription medicines and vaccines across five therapeutic areas: oncology, vaccines, infectious diseases (including HIV, Ebola, and antibiotics), diabetes, and anesthesia. Its product portfolio spans pneumococcal and HPV vaccines, immunotherapy-based oncology treatments, 35 years of HIV research output, and anesthesia medicines used in surgical settings, supported by complementary resources such as the MSD Manuals medical reference library and the Nivi AI-powered health chatbot developed under the MSD for Mothers global initiative.

The business operates on a sales-led go-to-market model, deploying field representatives to engage healthcare professionals directly and maintaining a dedicated Medical Affairs team for scientific engagement. Distribution flows through traditional pharmaceutical channels, including hospitals, pharmacies, and healthcare providers, with a dedicated healthcare practitioner portal (MSD Connect) for medical information access. Pricing is not publicly disclosed and is negotiated through Belgian reimbursement frameworks with health authorities. The company does not develop drugs locally; instead, it commercializes parent-company discoveries produced through cryo-electron microscopy, machine learning for clinical trial analysis, biomarker-based translational research, and the Center for Observational and Real-World Evidence (CORE).

Customer-facing activity extends beyond product sales into health literacy programs (klarekijkopkanker.be for cancer screening awareness), patient empowerment partnerships with organizations such as the one led by Prof. Eeckman, the Health Dialogue podcast series, and corporate social responsibility initiatives including the MSD Gives Back volunteer program. Strategic alignment with the Superior Health Council of Belgium on pneumococcal vaccination policy anchors the franchise in public health frameworks, while 'innovation beyond the pill' digital initiatives including Bingli remote patient monitoring signal incremental expansion into health services and software-enabled engagement channels.

Name

MSD Belgium

Legal name

Merck & Co., Inc.

Website

https://msd-belgium.be

Company type

Public

Founded year

1965

Operating status

Operating

Headcount range

101–250 employees

Short description

MSD Belgium is the Brussels-based Belgian subsidiary of Merck & Co. (NYSE: MRK), commercializing innovative prescription medicines and vaccines in oncology, vaccines, infectious diseases, diabetes, and anesthesia through field sales to healthcare providers and pharmacies across Belgium.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals and Vaccines

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

akta.pro secondary industries

Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Vaccines & Public Health Product Distribution (CRAOAHAI)

Keywords

• Prescription pharmaceuticals
• Biopharmaceutical medicines
• Vaccines and immunization
• Oncology therapeutics
• Infectious disease treatments

Headquarters

HQ city

Brussels

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical Products and Vaccines: MSD Belgium generates revenue through the sale of prescription medicines, vaccines, and biopharmaceutical products. The company develops and commercializes innovative medicines across multiple therapeutic areas including oncology, infectious diseases, vaccines, diabetes, and anesthesia, distributing through healthcare providers and pharmacies in Belgium.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

MSD Belgium develops, manufactures, and commercializes innovative prescription medicines and vaccines across five therapeutic areas: oncology, vaccines, infectious diseases (including HIV and Ebola), diabetes, and anesthesia. The company distributes these products in Belgium through field-sales engagement with healthcare professionals, hospitals, and pharmacies, supported by a Medical Affairs team and the MSD Connect professional portal. It complements its pharmaceuticals with patient engagement programs, health literacy initiatives, and digital health platforms.

Product overview

MSD Belgium operates as the Belgian subsidiary of Merck & Co., Inc., a global biopharmaceutical company. The company's product portfolio consists of innovative prescription medicines and vaccines focused on five core therapeutic areas: Oncology (cancer treatments including immunotherapy), Vaccines (disease prevention including pneumococcal and HPV vaccines), Infectious Diseases (including HIV, Ebola, and antibiotics with 35 years of HIV research), Diabetes (type 2 diabetes treatments), and Anesthesia (surgical medicines). MSD Belgium also supports patient care through complementary services including the MSD Manuals medical reference, the Nivi AI-powered health chat platform developed under MSD for Mothers, and Medical Connect for healthcare professional engagement. The company's innovation beyond the pill strategy includes digital health solutions and patient empowerment programs. The research and development pipeline is supported by the Center for Observational and Real-World Evidence (CORE), cryo-electron microscopy, machine learning for clinical trials, and tumor genetics/genomics research.

Differentiator

Problem solved

Functional benefit

Products and services

• Oncology Medicines

Quantifiable outcome

• 5800 hospitalizations and 430 deaths annually in Belgium adults above 50 due to pneumococcal diseases
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• Various Belgian Non-profit OrganizationsminorOthers · 1 September 2020During the MSD Gives Back Days in September 2020, more than 200 MSD Belgium colleagues volunteered to support Belgian non-profit organizations survive the corona pandemic. Activities included supporting hospitals and healthcare facilities during COVID-19.
• Patient EmpowermentcoreStrategic or Co-development PartnerMSD supports the non-profit organization 'Patient Empowerment' led by Prof. Eeckman. The organization focuses on maintaining, restoring, or reinforcing patient autonomy when illness affects independence. MSD collaborates with this organization to empower patients and help them maintain a sense of control over their healthcare decisions.
• Global Public-Private Partnership (Ebola)coreStrategic or Co-development PartnerMSD participates in a global public-private partnership united to combat the Ebola virus. This partnership has brought together government, industry, community groups, scientists, healthcare workers, and ordinary people to fight this deadly disease since its emergence in 1976.
• Cliniclowns BelgiumminorStrategic or Co-development PartnerMSD Belux provides dedicated grants to Cliniclowns Belgium to support their visits to sick or disabled children in hospitals. Cliniclowns send professional clowns to provide comfort, distraction, and fun to young patients, bringing joy during difficult hospital stays.
• Superior Health Council of BelgiumcoreOthersMSD Belgium works in alignment with Belgian health authorities including the Superior Health Council, which has been recommending pneumococcal vaccination for healthy adults above the age of 65 and certain at-risk groups since 2014.
• MSD for MothersminorOthersMSD for Mothers is the company's global initiative to help create a world where no woman has to die while giving life. The initiative supported the development of Nivi, an interactive mobile chat service for health topics including COVID-19, maternal health, and reproductive health.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Pfizer Belgium: Pfizer's Belgian subsidiary sells prescription medicines and vaccines across oncology, infectious diseases, and primary care. It directly competes with MSD Belgium across multiple therapeutic areas in the same Belgian market with similar HCP engagement models.
• Roche Belgium: Roche's Belgian operations focus on oncology, diagnostics, and specialty care. As a fellow multinational pharma subsidiary in Belgium, Roche competes head-to-head with MSD Belgium particularly in oncology and offers comparable scientific engagement to healthcare professionals.
• AstraZeneca Belgium: AstraZeneca Belgium markets oncology, respiratory, and cardiovascular medicines. As a fellow multinational pharma subsidiary, it competes with MSD Belgium particularly in oncology and operates with comparable field-sales engagement.
• GSK Belgium: GSK Belgium is a direct competitor in vaccines, HIV, and respiratory medicines. It competes with MSD Belgium on pneumococcal and HPV vaccines in particular, and operates with comparable HCP engagement and public-health authority relationships.
• Sanofi Belgium: Sanofi Belgium sells vaccines, diabetes treatments, and specialty care products, overlapping with MSD Belgium in vaccines and diabetes. It is one of the largest pharma subsidiaries in Belgium and a direct commercial competitor.
• Bayer Belgium: Bayer Belgium markets prescription pharmaceuticals across women's health, oncology, and cardiology. As a fellow multinational pharma subsidiary, it competes with MSD Belgium in overlapping therapeutic areas within the Belgian market.
• Janssen Belgium (Johnson & Johnson): Janssen Belgium is J&J's pharmaceutical subsidiary, active in oncology, infectious diseases, and immunology. It directly competes with MSD Belgium across multiple therapeutic areas with similar scientific engagement models.
• AbbVie Belgium: AbbVie Belgium focuses on oncology, immunology, and neuroscience. It competes with MSD Belgium in oncology and specialty care, and operates with similar HCP engagement and access strategies in the Belgian market.
• Bristol-Myers Squibb Belgium: BMS Belgium sells oncology, immunology, and cardiovascular drugs — directly overlapping with MSD Belgium's oncology and specialty portfolio. It is a fellow multinational pharma subsidiary with comparable medical affairs engagement.
• Novartis Belgium: Novartis Belgium markets innovative medicines across oncology, cardiovascular, and immunology — overlapping with MSD Belgium's therapeutic footprint. Operates with a similar large-pharma sales-led model and medical affairs engagement in Belgium.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MSDBelgium
• YouTubeyoutube.com/channel/UCLLeC8viOM3sTxDR8Zn_8RA
• Facebookfacebook.com/MSDinBelgium
• LinkedInlinkedin.com/company/msd-belgium
• Instagraminstagram.com/msdbelgium

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD Belgium